Condition (MeSH)
Osteolysis, Essential
ClinicalTrials.gov lists 5 trials for Osteolysis, Essential or a narrower condition beneath it. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) has the most among industry and government lead sponsors, with 1.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
5 of the 5 trials are tagged with Osteolysis, Essential itself; the rest are tagged with a narrower condition beneath it.
When did Osteolysis, Essential trials start? (5)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Not applicable
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2023 | 1 |
| 2016 | 1 |
| 2015 | 1 |
| 2013 | 1 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 5 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Osteolysis, Essential trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Not applicable | 1 |
| Observational | 4 |
How many Osteolysis, Essential trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 3 |
| Completed | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Osteolysis, Essential trials? (1)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
Which publications cover Osteolysis, Essential? (3)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Clinical features and current management experience in Gorham-Stout disease: a systematic review. | Orphanet journal of rare diseases | 2025 | Yes |
| Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease. | Pediatric blood & cancer | 2019 | Yes |
| Revision of cementless total knee arthroplasty with massive osteolytic lesions. | The Journal of arthroplasty | 1994 | Yes |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.